Optional Sub-study to Intraoperative Imaging With ICG Registry

Abramson Cancer Center at Penn Medicine

Status: Completed

Conditions: Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer; Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer; Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer

Treatments: Other: data collection

Study type: Observational

Funder types: Other

Identifiers

NCT02651246

UPCC 31915

Details and patient eligibility

About

The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.

Full description

Our objective is to collect prospective data on cancer subjects who undergo surgery and intraoperative imaging. The registry will include (but not limited to) cancer type, stage, intraoperative challenges to the surgeon, usage and results of intraoperative imaging, and recurrence surveillance.

In this protocol, subjects that receive intraoperative imaging will provide us the opportunity to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed. Also, we will monitor any side effects or potential toxicities that may occur. This data can then be used to predict if a subject is more likely to develop a local recurrence due to missed cancer cells, metastatic lymph nodes or synchronous lesions.

Enrollment: 291 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients >= 18 years of age
• Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and are at risk for recurrence.
• Good operative candidate as determined by the treating physician and/or multidisciplinary team
• Subject capable of giving informed consent and participating in the process of consent.

Exclusion criteria

• Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery
• Vulnerable patient populations